A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Acute Myeloid Leukemia Clinical Trial

Official title:

A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06146257
• Other study ID #: GLB-001-01
• Status: Recruiting
• Phase: Phase 1
• Start date: January 11, 2024
• Est. completion date: October 8, 2026

Study information

• Verified date: February 2024
• Source: GluBio Therapeutics Inc.
• Contact: Hongying Zhang, MD
• Phone: 619-859-4586
• Email: Hongying.Zhang[@]glubiotx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The dose escalation part (Phase 1a) of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 administered orally. Approximately 24 participants (up to 42 participants) may be enrolled in Phase 1a of the study. The dose expansion part (Phase 1b) will be followed to understand the relationships among dose, exposure, toxicity, tolerability and clinical activity, to identify minimally active dose, and to select the recommended dose(s) for phase 2 study. Up to 24 participants (12 participants per dose level) may be enrolled in Phase 1b of the study.

Description:

A standard 3+3 dose-escalation design will be applied to evaluate a set of several dose levels to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of GLB-001 in R/R AML or R/R HR-MDS patients who are eligible for DLT evaluation. The actual dose-escalation magnitude or dosing frequency may be adjusted based on the available PK and safety data in human. After the MTD or MAD of GLB-001 is defined in Phase 1a, 1 or 2 dose levels will be selected for expansion per safety review committee (SRC) recommendation, approximately 12 patients will be enrolled per dose level. Recommended phase 2 dose (RP2D) will be selected based on the results of PK, PD, safety and efficacy in the dose escalation and expansion study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: October 8, 2026
• Est. primary completion date: October 6, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants is = 18 years of age at the time of signing the Informed Consent Form (ICF).
• Participants must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
• Participants are willing and able to adhere to the study visit schedule and other protocol requirements.
• Participants with histologically or cytologically confirmed AML including de novo AML or secondary AML transformed from MDS according to 2022 World Health Organization (WHO) criteria classification, or with histologically or cytologically confirmed HR-MDS.
• R/R AML and R/R HR-MDS who have failed or are ineligible for all available therapies which may provide clinical benefit.
• Participants must have the following screening laboratory values:
• Total white blood cell count (WBC) < 25 x 10^9/L prior to the first dose of the study drug.
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 × upper limit of normal (ULN), unless considered due to extensive leukemic liver involvement, in which case AST and ALT can be = 5.0 x ULN.
• Serum total bilirubin = 1.5 x ULN, unless considered due to Gilbert's syndrome, in which case serum total bilirubin < 3 x ULN.
• Estimated serum creatinine clearance of = 60 mL/min using the Cockcroft-Gault equation. Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated.
• International normalized ratio (INR) = 1.5 x ULN and active partial thromboplastin time (aPTT) = 1.5 x ULN.
• Life expectancy = 12 weeks.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
• Female Participants of child-bearing potential must have a negative serum or urine pregnancy test at screening and at pre-dose on Cycle 1 Day 1 (C1D1).

Exclusion Criteria:

• Participants with acute promyelocytic leukemia (APML).
• Participants with known leukemic involvement in central nervous system (CNS).
• Receipt of anticancer medications/therapies within 5 half-lives or 28 days before the first administration of the study drug.
• Participants with unresolved clinically significant non-hematologic toxicities of = Grade 2 AE from prior therapies with exception of residual alopecia.
• Participants with chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy.
• Participants with active malignancies other than AML or MDS.
• Participants who have undergone major surgery = 4 weeks prior to the first dose of the study drug.
• Participants with immediately life-threatening, severe complications of leukemia such as disseminated/uncontrolled infection (bacterial and/or fungal), uncontrolled bleeding, and/or uncontrolled disseminated intravascular coagulation.
• Participants with known chronic, active infection of hepatitis B virus (HBV), hepatitis C virus C (HCV), human immunodeficiency virus (HIV).
• Participants unable to swallow oral medications, or Participants with clinically significant diarrhea, vomiting or malabsorption felt limited absorption of orally administered medications.
• Participants with any other significant medical conditions, any other conditions, laboratory abnormality, or psychiatric illness which place the Participants at unacceptable risk if he/she were to participate in the study or that would hamper the Participants understanding of the study, or would prevent the Participant from complying with the study.
• Medications or supplements that are known to be strong and moderate inhibitors or inducers of CYP450 isozyme 3A4 (CYP3A4) and/or P-glycoprotein (P-gp), or strong inhibitors or inducers of CYP450 isozyme 2C8 (CYP2C8) within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug.
• Pregnant or lactating women.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• GLB-001
Administered orally according to the assigned treatment schedule

Locations

Country	Name	City	State
United States	Roswell Park Comprehensive Cancer Center	Buffalo	New York
United States	City of Hope Medical Center	Duarte	California
United States	University of Texas M. D. Anderson Cancer Center	Houston	Texas
United States	University of California Irvine	Irvine	California
United States	University of Kansas Medical Center Research Institute, Inc.	Kansas City	Kansas
United States	Alliance for Multispecialty Research, LLC	Merriam	Kansas
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Memorial Sloan Kettering Cancer Center-David H. Koch Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
GluBio Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting Toxicity (DLT)	Dose-limiting toxicity is defined as the treatment emergent adverse events (TEAEs) meeting protocol specified DLT criteria and occurring within the DLT assessment period.	Up to 28 days after first dose of study treatment in Phase 1a
Primary	Maximum Tolerated Dose (MTD)/Maximum Administered Dose (MAD)	Maximum tolerated dose is defined as the highest dose level at which no more than 1 of 6 DLT-evaluable participants experienced a DLT. If MTD is not established at the end of dose escalation phase, the maximum safety dose will be defined as Maximum administered dose.	Up to 2 years
Primary	Incidence of Adverse Events (AEs)	Adverse Events will be graded according to the National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) version 5.0.	Up to 2 years
Primary	Recommended Phase 2 Dose (RP2D)	Recommended phase 2 dose based on the totality of data across dosing cohorts in the dose escalation and expansion phases of the study including PK, PD, safety and efficacy outcomes.	Up to 2 years
Secondary	GLB-001 Pharmacokinetics-AUC0-last	Area under the concentration-time curve from zero to the last measurable concentration.	Up to 2 years
Secondary	GLB-001 Pharmacokinetics-AUC0-24	Area under the concentration-time curve from 0 to 24 hours.	Up to 2 years
Secondary	GLB-001 Pharmacokinetics-AUC0-8	Area under the concentration-time curve from 0 to infinity.	Up to 2 years
Secondary	GLB-001 Pharmacokinetics-Cmax	Maximum plasma concentration.	Up to 2 years
Secondary	GLB-001 Pharmacokinetics-Tmax	The time to reach maximum concentration.	Up to 2 years
Secondary	GLB-001 Pharmacokinetics-T1/2	Terminal half-life.	Up to 2 years
Secondary	GLB-001 Pharmacokinetics-Vd/F	Apparent volume of distribution.	Up to 2 years
Secondary	GLB-001 Pharmacokinetics-LI	Linear index.	Up to 2 years
Secondary	GLB-001 Pharmacokinetics-CL/F	Apparent clearance.	Up to 2 years
Secondary	GLB-C183-A-2R (Isomer of GLB-001) Pharmacokinetics-AUC0-last	Area under the concentration-time curve from zero to the last measurable concentration.	Up to 2 years
Secondary	GLB-C183-A-2R Pharmacokinetics-AUC0-24	Area under the concentration-time curve from 0 to 24 hours.	Up to 2 years
Secondary	GLB-C183-A-2R Pharmacokinetics-AUC0-8	Area under the concentration-time curve from 0 to infinity.	Up to 2 years
Secondary	GLB-C183-A-2R Pharmacokinetics-Cmax	Maximum plasma concentration.	Up to 2 years
Secondary	GLB-C183-A-2R Pharmacokinetics-Tmax	The time to reach maximum concentration.	Up to 2 years
Secondary	GLB-C183-A-2R Pharmacokinetics-T1/2	Terminal half-life.	Up to 2 years
Secondary	GLB-C183-A-2R Pharmacokinetics-Vd/F	Apparent volume of distribution.	Up to 2 years
Secondary	GLB-C183-A-2R Pharmacokinetics-LI	Linear index.	Up to 2 years
Secondary	GLB-C183-A-2R Pharmacokinetics-CL/F	Apparent clearance.	Up to 2 years
Secondary	Complete Remission Without Minimal Residual Disease (CRMRD-) Rate in Participants with Acute Myeloid Leukemia (AML)	CRMRD- rate is defined as the percent of participants with minimal residual disease negative complete remission. CRMRD- will be assessed by the 2022 European Leukemia Net Response Criteria (2022 ELN) for AML .	Up to 2 years
Secondary	Complete Remission (CR) Rate in Participants with AML	CR rate is defined as the percent of participants whose best response is CR. CR will be assessed by 2022 ELN for AML.	Up to 2 years
Secondary	CR with Incomplete Hematologic Recovery (CRi) Rate in Participants with AML	CRi rate is defined as the percent of participants whose best response is CRi. CRi will be assessed by 2022 ELN for AML.	Up to 2 years
Secondary	CR with Partial Hematological Recovery (CRh) Rate in Participants with AML	CRh rate is defined as the percent of participants whose best response is CRh. CRh will be assessed by 2022 ELN for AML.	Up to 2 years
Secondary	Morphologic Leukemia-free State (MLFS) Rate in Participants with AML	MLFS rate is defined as the percent of participants with the best response of morphologic leukemia-free state. MLFS will be assessed by 2022 ELN for AML.	Up to 2 years
Secondary	Partial Remission (PR) Rate in Participants with AML	PR rate is defined as the percent of participants whose best response is PR. PR will be assessed by 2022 ELN for AML.	Up to 2 years
Secondary	Duration of Remission or Response (DOR) in Participants with AML	For participants with best response of any of CRMRD-, CR, CRh, CRi, PR, and MLFS, DOR is measured from the time when criteria (2022 ELN for AML) for the best response of any of CRMRD-, CR, CRh, CRi, PR, and MLFS are first met (whichever is first recorded) until the first date at which relapse, or progressive disease is objectively documented assessment.	Up to 2 years
Secondary	Time to Remission or Response (TOR) in Participants with AML	Time to onset of first remission or response is defined as the time interval from the date of first dose and the earliest date any remission or response [any CRs (including CR, CRh and CRi) or PR] is observed.	Up to 2 years
Secondary	Stable Disease (SD) Rate in Participants with AML	SD rate is defined as the percent of participants with the best response of stable disease. SD will be assessed by 2022 ELN for AML.	Up to 2 years
Secondary	CR Rate in Participants with Higher Risk Myelodysplastic Syndromes (HR-MDS)	CR rate is defined as the percent of participants whose best response is CR. CR will be assessed by 2006 Modified International Working Group (IWG) MDS response criteria.	Up to 2 years
Secondary	PR Rate in Participants with HR-MDS	PR rate is defined as the percent of participants whose best response is PR. PR will be assessed by 2006 Modified IWG MDS response criteria.	Up to 2 years
Secondary	SD Rate in Participants with HR-MDS	SD rate is defined as the percent of participants with the best response of stable disease. SD will be assessed by 2006 Modified IWG MDS response criteria.	Up to 2 years
Secondary	DOR in Participants with HR-MDS	For participants with best response of any of CR, marrow CR, or PR, DOR is measured from the time when criteria (2006 Modified IWG MDS response criteria) for the best response of any of CR, marrow CR, or PR are first met (whichever is first recorded) until the first date at which relapse or progressive disease is objectively documented assessment.	Up to 2 years
Secondary	TOR in Participants with HR-MDS	Time to onset of first remission or response is defined as the time interval from the date of first dose of GLB-001 and the earliest date any remission or response [any CRs (including CR, marrow CR or PR)] is observed.	Up to 2 years
Secondary	Progression-free Survival (PFS) in Participants with AML or HR-MDS	PFS is defined as the time from the first dose of GLB-001 to the first occurrence of relapse or progression or death from any cause.	Up to 2 years
Secondary	Overall Survival (OS) in Participants with AML or HR-MDS	OS is defined as the time from the first dose of GLB-001 to death due to any cause.	Up to 2 years